Irny 500mg Injection contains Ferric Carboxymaltose, a parenteral iron preparation indicated for the treatment of iron deficiency anemia when oral iron preparations are ineffective or cannot be used. This formulation provides a controlled release of bioavailable iron, facilitating rapid replenishment of iron stores and correction of hemoglobin levels. Irny 500mg Injection is administered intravenously, allowing for efficient iron delivery directly into the bloodstream, which is particularly beneficial in patients with chronic kidney disease, inflammatory bowel disease, or those undergoing hemodialysis. The injection is typically given in a clinical setting under medical supervision to monitor for potential hypersensitivity reactions. Ferric Carboxymaltose has a favorable safety profile, with common adverse effects including mild transient headache, nausea, dizziness, and injection site reactions. It is contraindicated in patients with known hypersensitivity to the active substance or any of the excipients, and in cases of iron overload disorders such as hemochromatosis. Dosage and administration should be individualized based on the patient’s iron deficit, body weight, and hemoglobin concentration, following established clinical guidelines. Irny 500mg Injection offers an effective and well-tolerated option for rapid iron repletion in patients requiring parenteral iron therapy.